openPR Logo
Press release

Stargardt Disease Therapeutics Market Insights With Key Players Nemus Bioscience , Acucela , Katairo, Ocata Therapeutics , Sanofi

01-04-2019 04:33 PM CET | Health & Medicine

Press release from: Coherent Market Insights - Pharmaceutical Industry

Stargardt Disease Therapeutics

Stargardt Disease Therapeutics

Treatment options for Stargardt disease include drug, gene therapy and stem cell therapy. There are products in each of these category currently in clinical trials. For instance, Nightstar Therapeutics expanded its pipeline with gene therapy program for Stargardt Disease treatment in November 2017. In drug category, certain companies have received orphan drug designation from U.S. FDA. For instance, in January 2017, Acucela Inc. received orphan drug designation for its leading product emixustat for the treatment of stargardt disease. In October 2017, Lin BioScience also received orphan n drug designation for its leading product LBS-008 for the treatment of Stargardt Disease. Furthermore, companies such as Astellas Pharma Inc. is working on stem cell therapy for Stargardt disease. With the approval of some of the therapy that are currently in pipeline, the global stargardt disease therapeutics market is expected to witness rapid growth over the forecast period.

Get Discount On This Report:
www.coherentmarketinsights.com/insight/request-discount/1314

Stargardt Disease Therapeutics Market Taxonomy:

By Treatment Type:

Drugs
Gene Therapy
Stem Cell Therapy
By Stages of Development:

Children
Adult

Acucela Inc. and Lin Bioscience have received orphan drug designation for their respective products, and are headquartered in U.S. Other companies such as Astellas Pharma Inc, Copernicus Therapeutics Inc. and Sanofi S.A. are either U.S.-based or have considerable presence in U.S. This positions North America as a major market for stargardt disease. Europe is expected to hold second position in stargardt disease therapeutics market as companies like Nightstar therapeutics has shown interest in developing treatment for stargardt disease. In Asia Pacific region, Japan is home to companies such as Astellas Pharma Inc. Also, major Japan-based pharmaceutical companies are working with small-size Company operating in this area. For instance, Otsuka Pharmaceutical Co., Ltd., a Japan-based company, has continued its collaboration agreement with Acucela Inc., a clinical stage company working on stargardt disease, since 2008.

Stargardt disease is an inherited juvenile macular degeneration that causes vision loss. The signs and symptoms of the disease typically appear in late childhood or early adulthood and worsen with time. The most common cause of the disease is mutations in the ABCA4 gene. People suffering from stargardt disease might notice grey or black color in the middle of eye, or eyes may be more sensitive to bright light. Others may even have symptoms of color blindness. The prevalence for the disease is low, reported at around 1 in 8,000-10,000 people globally, as stated by National Eye Institute in April 2015. Hence, the disease falls into rare disease category. Till date, there is no treatment available, though there are multiple therapies in pipeline.

Download the PDF brochure:
www.coherentmarketinsights.com/insight/request-pdf/1314

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Stargardt Disease Therapeutics Market Insights With Key Players Nemus Bioscience , Acucela , Katairo, Ocata Therapeutics , Sanofi here

News-ID: 1472327 • Views: 1101

More Releases from Coherent Market Insights - Pharmaceutical Industry

Global Myelodysplastic Syndrome (MDS) Treatment Market Balenced To Reach Insigni …
Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around
Global Opioids Agonist Drugs Market Is Recurring & Impressive Growth Generating …
Opioid drugs act on the opioid receptors present in the central and peripheral nervous system. The drug class primarily used in relieving pain includes natural, semi-synthetic, and synthetic opioids. Codeine, morphine, hydrocodone, oxycodone, heroin, and fentanyl are some of the major prescription drugs in the global opioids agonist drugs market. Opioids can be administered as oral pills, parenteral, liquids, patches, or lozenges. Overdose and drug abuse is a major concern
Pediatric Nutrition Market is Booming 2019 by Top Key Players Reckitt Benckiser …
Pediatric nutrition is an important source of nutritional supplement for babies during their formative years. These products are available in milk-based, Soy-based, amino acid-based, and organic forms. These nutritional products support brain development and also helps in the management of allergies and metabolic disorder. Highest number of births are recorded in Asia Pacific, and hence, the region holds maximum opportunity for market players. Lactose intolerance, allergy to cow’s protein milk,
Dravet Syndrome Treatment Market: Business Planning Research, Reviews & Comparis …
Dravet syndrome (DS), also known as epilepsy with polymorphic seizures and polymorphic epilepsy in infancy (PMEI), is a severe and rare genetic dysfunction of the brain (epileptic encephalopathy). It usually begins in first year of life and remains throughout lifetime. Children suffering from dravet syndrome suffer from different type of seizures namely, myoclonic seizures, tonic-clonic seizures, absence seizures, atypical absence seizures, atonic seizures, focal aware or impaired awareness seizures (previously

All 5 Releases


More Releases for Stargardt

New study: Stargardt Disease Therapeutics and In-depth Research on Market Size, …
Stargardt Disease Therapeutics Market is expected to have a highly positive outlook for the next five years 2018-2026 according to a recently released Stargardt Disease Therapeutics Market research report. The report has been added in his large database by Coherent Market Insights. This report is a guide which covers key strategic developments of the market including acquisitions & mergers, new technology launch, agreements, partnerships, collaborations & joint ventures, research &
Stargardt Disease Pharmaceutical and Healthcare Analysis Information
Introduction Juvenile Macular Degeneration is the genetic eye disorder that affects the vision further leading to vision loss. Generally, this disorder affects the specialized light-sensitive tissue present in the retina. Precisely, this type of macular degeneration affects the center of the retina which is knewn as macula. The function of macula is to add sharpness to the central vision. This region is responsible for handling detailed tasks such as recognizing
Global Stargardt Disease Market Research Report 2018 Analysis and Forecast to 20 …
Introduction Juvenile Macular Degeneration is the genetic eye disorder that affects the vision further leading to vision loss. Generally, this disorder affects the specialized light-sensitive tissue present in the retina. Precisely, this type of macular degeneration affects the center of the retina which is knewn as macula. The function of macula is to add sharpness to the central vision. This region is responsible for handling detailed tasks such as recognizing
Stargardt Disease Therapeutics Market by Treatment Type (Drugs, Gene Therapy, an …
Stargardt disease is an inherited juvenile macular degeneration that causes vision loss. The signs and symptoms of the disease typically appear in late childhood or early adulthood, and worsen with time. The most common cause of the disease is mutations in the ABCA4 gene. People suffering from stargardt disease might notice grey or black colour in the middle of eye, or eyes may be more sensitive to bright light. Others
North America is expected to hold a dominant position in the global stargardt di …
Stargardt disease is an inherited juvenile macular degeneration that causes vision loss. The signs and symptoms of the disease typically appear in late childhood or early adulthood, and worsen with time. The most common cause of the disease is mutations in the ABCA4 gene. People suffering from stargardt disease might notice grey or black colour in the middle of eye, or eyes may be more sensitive to bright light. Others
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2017, provides an overview of the Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) pipeline landscape. Juvenile macular degeneration is a series of inherited eye disorders